Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
Phase 2
Terminated
- Conditions
- Neuromuscular Disease
- Interventions
- Drug: A0001 (alpha-tocopherolquinone)Drug: Placebo
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Penwest Pharmaceuticals Co.
- Target Recruit Count
- 30
- Registration Number
- NCT01074359
- Locations
- 🇬🇧
University of Newcastle upon Tyne, Newcastle, Framlington Place, United Kingdom
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
Phase 2
Completed
- Conditions
- Friedreich's Ataxia
- Interventions
- Drug: placebo
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Penwest Pharmaceuticals Co.
- Target Recruit Count
- 42
- Registration Number
- NCT01035671
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath